Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.74 |
| ▸ | VCP | P55072 | 4/20 | 0.55 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.51 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | CCR6 | P51684 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4501431 | 1.00 | PRMT1 (0.74) | PRMT1VCPABCG2CYP1A1CYP1B1 | |
| SCHEMBL14812451 | 1.00 | PRMT1 (0.74) | PRMT1VCPABCG2CYP1A1CYP1B1 | |
| SCHEMBL34463115 | 0.87 | PRMT1 (0.66) | PRMT1VCPABCG2ALDH1A1MAPT | |
| SCHEMBL5712541 | 0.86 | PRMT1 (0.64) | PRMT1VCPALDH1A1MAPTLMNA | |
| SCHEMBL5712544 | 0.86 | PRMT1 (0.64) | PRMT1VCPALDH1A1MAPTLMNA | |
| SCHEMBL1011167 | 0.85 | PRMT1 (1.00) | PRMT1VCPCYP1A1CYP1B1CYP19A1 | |
| SCHEMBL1011169 | 0.85 | PRMT1 (1.00) | PRMT1VCPCYP1A1CYP1B1CYP19A1 | |
| SCHEMBL193398 | 0.82 | PRMT1 (0.59) | PRMT1VCPALDH1A1MAPTLMNA | |
| SCHEMBL151935 | 0.82 | PRMT1 (0.59) | PRMT1VCPALDH1A1MAPTLMNA | |
| SCHEMBL130011 | 0.82 | PRMT1 (0.59) | PRMT1VCPALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155259-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2018-12-18 | — | — | US | disclosed |
| EP-2763986-B1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (NL) | 2017-06-07 | — | — | EP | disclosed |
| CN-105265432-A | Application of (E)-1,2,3-trimethoxy-beta-nitrostyrolene | SHANGHAI INST TECHNOLOGY | 2016-01-27 | — | — | CN | disclosed |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2015-11-19 | — | — | US | disclosed |
| US-9127007-B2 | FSH receptor antagonists | MERCK SHARP & DOHME B.V. (NL) | 2015-09-08 | — | — | US | disclosed |
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME B.V. (NL) | 2014-11-27 | — | — | US | disclosed |
| EP-2763986-A1 | FSH RECEPTOR ANTAGONISTS | Merck Sharp & Dohme B.V. (NL) | 2014-08-13 | — | — | EP | disclosed |
| WO-2013041458-A1 | FSH RECEPTOR ANTAGONISTS | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
| US-20090023728-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20090023728-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-22 | — | — | US | disclosed |
| CN-1655783-A | Phosphodiesterase iv inhibitor containing pyridylacrylamide derivative | TSUMURA & CO (JP) | 2005-08-17 | — | — | CN | disclosed |
| US-5866513-A | Aryl-substituted cycloalkanes and cycloalkenes and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1999-02-02 | — | — | US | disclosed |
| EP-0768298-A1 | Aryl-substituted cycloalkanes and cycloalkenes and herbicidal use thereof | ROHM AND HAAS COMPANY (US) | 1997-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350043-A1 | FSH RECEPTOR ANTAGONISTS | FSHR, GNRHR, LHCGR | PRMT1 1380/4885VCP 3014/4885ABCG2 4478/4885 |
| US-20090023728-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof | OPRD1, QDPR, RECQL | PRMT1 182/4885VCP 4460/4885ABCG2 176/4885 |
| US-10155259-B2 | FSH receptor antagonists | FSHR, GNRHR, LHCGR | PRMT1 1156/4885VCP 2984/4885ABCG2 4491/4885 |
| US-20150329545-A1 | FSH RECEPTOR ANTAGONISTS | FSHR, GNRHR, LHCGR | PRMT1 1156/4885VCP 2984/4885ABCG2 4491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.